|
| ID |
DDInter448 |
| Drug Type |
small molecule |
| Molecular Formula |
C21H22Cl2Fn5O |
| Molecular Weight |
450.345
|
| Description |
Crizotinib is a receptor tyrosine kinase inhibitor used to treat metastatic non-small cell lung cancer (NSCLC) where the tumors have been confirmed to be anaplastic lymphoma kinase (ALK), or ROS1-positive.
|
| ATC Classification |
L01XE16
|
| IUPAC Name |
3-[(1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy]-5-[1-(Piperidin-4-Yl)-1H-Pyrazol-4-Yl]Pyridin-2-Amine |
| InChI |
Inchi=1S/C21H22Cl2Fn5O/C1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/H2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/T12-/M1/S1 |
| InChI Key |
KTEIFNKAUNYNJU-GFCCVEGCSA-N |
| Canonical SMILES |
C[C@@H](OC1=CC(=CN=C1N)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl |
| Useful Links |
DrugBank
ChEMBL
PubChem
|